PubMed Health⌕ Search

Biomedical subjects

Y Lo

Publications and source records attributed to Y Lo.

27 records · Page 2Linked to original sources

Trihexyphenidyl abuse in schizophrenic patient: a case report.

Trihexyphenidyl is a synthetic anticholinergic used in psychiatric patient for the relief of neuroleptic-induced extrapyramidal symptoms. It has been reported to have mood elevating, euphorigenic and socially-stimulating effects. The case presented is of anti-cholinergic abuse by a chronic schizophrenic who abused trihexyphenidyl, up to 200 mg per day, to achieve an euphoric effect. The drug was partly prescribed in psychiatric clinics, but mostly bought in the drugstore. The discontinuance of trihexyphenidyl produced anxiety, which was relieved by anxiolytics. The patient also feigned extrapyramidal symptoms to get anticholinergic injections during drug abstinence. A high dose of trihexyphenidyl may precipitate anticholinergic toxic psychosis and interfere with the therapeutic effects of antipsychotics by impeding their absorption. Given a large number of patients receiving this medication, clinicians should be alert when prescribing this drug, especially for patients who have abuse potential. As this agent has never been under public surveillance and is available in local pharmacies, the health authorities should be concerned with its abuse potential.

Adult↗

Plasticity of developing neuromuscular synapses.

Developing neuromuscular synapses are susceptible to modulation by the presence of synaptic activity and a number of chemical factors originated from either pre- or postsynaptic cells. In vitro studies of functional modulation of synaptic strength by electrical stimulation of pre- and postsynaptic cells suggested an essential role of retrograde interactions at developing synapses.

Animals↗

Anesthesia for elective cardioversion: a comparison of thiopentone and propofol.

BACKGROUND: Cardioversion is still a trend of therapy for cardiac dysrhythmias. With the application of new intravenous anesthetics, cardioversion can be performed safely and effectively with rapid onset of and quicker recovery from anesthesia. We compared the anesthetic effects of a new synthetic agent, propofol, with thiopentone which was mostly used in the past. METHODS: Twenty four ASA class II to III adult patients scheduled for elective cardioversion in the coronary care unit were included in this study. All patients were given fentanyl (2 micrograms/kg, i.v.) three min before induction and were randomly assigned to receive either thiopentone 1.5 mg/kg (group 1) or propofol 1 mg/kg (group 2) for induction of anesthesia. Supplementary oxygenation was administered throughout. RESULTS: Both drugs could provide satisfactory anesthesia for elective cardioversion without major complications. Recovery time was shorter with propofol (p < 0.05). Comparing with previous reports, a higher incidence of apnea and prolonged sedation were noted in this study. This might be due to the additive effect of thiopentone or propofol with fentanyl. CONCLUSIONS: Both anesthetics were suitable for elective cardioversion with negligible side effects in hemodynamically stable patients.

Aged↗

Septata intestinalis and Encephalitozoon cuniculi: cross-reactivity between two microsporidian species.

An infection with Septata intestinalis was diagnosed in a 35-year-old AIDS patient without diarrhoea. The diagnosis was based on morphological examinations of a duodenal biopsy specimen. Serum antibodies were detected reacting with spores of Encephalitozoon cuniculi. Spores of S. intestinalis and E. cuniculi stained with Brown Hopps Gram stain showed a red colour (Gram negative) and not a blue/black colour which was described for microsporidian spores in tissue.

AIDS-Related Opportunistic Infections↗

The effect of fractionated doses of radiation on mouse spinal cord.

PURPOSE: To determine: (a) the dose-response relationship and latent time to paralysis following fractionated doses of radiation in mice, (b) the values of parameters for isoeffect curves, and (c) whether these parameters depend on the size of dose per fraction and the severity of injury. METHODS AND MATERIALS: The spinal cords (T9-L5) of 608 C3Hf/Sed/Kam mice were irradiated with fractionated doses of x-radiation. Three levels of neurological damage were used to grade the spinal cord response. Animals which did not develop paralysis were observed for at least 18 months after irradiation. The fractionated schedules consisted of either 2, 3, 4, 6, 10, or 20 fractions in addition to single doses. For the fractionated regimes the daily fraction size ranged from 2 Gy to 24 Gy, and for single doses the range was 12 Gy to 52 Gy. Both the latent time to paralysis and the incidence of paralysis were considered as endpoints. For analysis of the sparing associated with fractionation, the dose points were divided into two groups: a "low damage" group consisting of doses of near or less than the ED50 at 450 days and a "high damage" group consisting of doses much larger than the ED50 at 450 days in which there was 100% incidence of paralysis. RESULTS: The latent time depended on the radiation dose; for each fixed fraction number the latent period became progressively shorter with higher total doses. Differences in histology in fractionation sensitivity are observed between the two groups. The low damage data in each fractionation treatment are the important data in the analysis of long-term incidence of paralysis. On the other hand, the high damage data were emphasized for the analysis of latency. Three statistical methods (mixture model, Cox model, and Fe-plot) were used to fit the linear-quadratic dose response model and the "Nominal Standard Dose" (NSD) model. The values of the parameters of these two models depended on the effect evaluated; the latent interval from the high damage region being not very fractionation-dependent, whereas, the incidence of paralysis from the low damage fractionation regimens was strongly dependent on dose per fraction. Specifically, the alpha/beta ratios for latency were large (e.g., 17 to 57 Gy) when fractionation schemes in the high damage region were emphasized. If data from the fractionation schemes in the lower damage region with fraction size less than 15 Gy were emphasized, the alpha/beta ratios for incidence of paralysis were 3.3 (1.8, 6.0, 95% C.I.), 4.1 (2.8, 5.5), and 4.4 Gy derived by the mixture, Cox, and Fe-plot models, respectively. These "low damage" alpha/beta ratios were similar for all levels of injury from mild to complete paralysis, and are those which are more relevant to clinical radiotherapy. The coefficients for the "Nominal Standard Dose" formula in the present study were 0.33 +/- 0.01 (s.e.) (by the Strandqvist-type plot), 0.38 (the Cox model), or 0.40 (the mixture model) for level 2 injury at 450 days. CONCLUSION: The values of parameters in the isoeffect models were different when the data analyzed were derived from regimens using fractionated low or high damage doses.

Animals↗

AHR-15010--a novel anti-arthritic agent.

AHR-15010 (3-(2-methoxyphenoxy)-1,2-propanediol bissulphamate ester) is a compound of novel structure that displays anti-arthritic activity in adjuvant arthritis in rats. When given orally from days 18 through day 50, (excluding weekends) after adjuvant injection, AHR-15010, at doses of 3.16 to 100 mg kg-1, produced significant anti-inflammatory activity and reduced the severity of the hind paw joint lesions as monitored by X-ray analysis. AHR-15010, however, has no acute anti-inflammatory activity in the Evans Blue-carrageenan pleural effusion assay in rats, has no analgesic activity in mice, and has no activity in a classic, delayed-type, hypersensitivity assay in mice or in a cotton pellet granuloma test in rats. These data, in conjunction with biochemical data showing that AHR-15010 has no prostaglandin synthetase inhibiting activity suggest that AHR-15010 is an anti-arthritic with a unique mechanism of action. AHR-15010 is a carbonic anhydrase inhibitor. Data are presented that suggest that AHR-15010 and acetazolamide, a prototype carbonic anhydrase inhibitor, may present novel approaches to the treatment of arthritis.

Animals↗